These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8730458)

  • 21. Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin.
    McMahon LP; Dawborn JK
    Am J Nephrol; 1990; 10(5):404-8. PubMed ID: 2080791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin.
    Barclay PG; Fischer ER; Harris DC
    Clin Nephrol; 1993 Nov; 40(5):277-80. PubMed ID: 8281716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subcutaneous erythropoietin: a comparison of daily and thrice weekly administration.
    Granolleras C; Branger B; Shaldon S; Nonnast-Daniel B; Koch KM; Pollok M; Baldamus CA
    Contrib Nephrol; 1991; 88():144-8; discussion 149-51. PubMed ID: 2040176
    [No Abstract]   [Full Text] [Related]  

  • 24. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study.
    Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L
    Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weekly subcutaneous erythropoietin maintains hematocrit in chronic hemodialysis patients.
    Parker KP; Sands JM
    J Am Soc Nephrol; 1993 Apr; 3(10):1717-8. PubMed ID: 8318688
    [No Abstract]   [Full Text] [Related]  

  • 27. Recombinant human erythropoietin in patients on peritoneal dialysis.
    Bargman J
    Perit Dial Int; 1989; 9(4):245-6. PubMed ID: 2488375
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
    Raja R; Bloom E; Johnson R
    Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The pharmacokinetics of recombinant human erythropoietin].
    Siniukhin VN; Stetsiuk EA; Lovchinskiĭ EV; Lebedev SV; Iarmolinskiĭ IS; Liakhov VV
    Ter Arkh; 1994; 66(8):60-2. PubMed ID: 7985158
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of recombinant human erythropoietin on hematopoietic progenitors of chronic hemodialysis patients in vitro and in vivo.
    Hino M; Miyazono K; Urabe A; Takaku F
    Int J Cell Cloning; 1989 Jul; 7(4):257-63. PubMed ID: 2768843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of subcutaneous low-dose erythropoietin in patients with chronic renal failure despite functional iron deficiency.
    Bedani PL; Cecchetti E; Gilli P
    Nephron; 1995; 71(4):459-60. PubMed ID: 8587628
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD.
    Icardi A; Paoletti E; Molinelli G
    Adv Perit Dial; 1990; 6():292-5. PubMed ID: 1982830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The effect of correcting anemia with recombinant erythropoietin on the central hemodynamic indices of patients on regular hemodialysis].
    Ermolenko VM; Khvoĭnitskiĭ VA; Suprun EK; Tsukerman LI; Pokrovskiĭ IuA
    Ter Arkh; 1992; 64(7):86-8. PubMed ID: 1440377
    [No Abstract]   [Full Text] [Related]  

  • 35. [Improvement of the quality of life for hemodialysis patients using recombinant human erythropoietin].
    Schaefer RM
    Krankenpfl J; 1988; 26(7-8):317-20. PubMed ID: 3419139
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients.
    Buemi M; Allegra A; Laganà A; Aloisi C; Privitera M; Morabito N; Frisina N
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):195-7. PubMed ID: 7761669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
    Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
    Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis. Prospective multicenter study].
    Ruedin P; Stoerman C; Pechère-Bertschi A; Leski M
    Nephrologie; 1992; 13(2):87-92. PubMed ID: 1608502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
    Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
    Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.